Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Toxins in hair and urine: could they trigger rare lung disease?

NCT ID NCT07172334

Knowledge-focused Sponsor: Poitiers University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study looks at whether environmental toxins, drugs, and workplace exposures play a role in causing pulmonary arterial hypertension (PAH), a rare and serious lung condition. Researchers will compare 150 newly diagnosed patients with PAH to those with another form of pulmonary hypertension (CTEPH) by testing their hair and urine for 180 toxins. The goal is to identify potential triggers that may help explain why some people develop PAH.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Major patients understanding French language with pre-capillary PH confirmed by cardiac catheterization during the year (PAH without associated pathology and CTEPH class 4)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Consent signed by the participant * Age ≥ 18 years * Free subject, under no legal protection * Good understanding of the French language, allowing to answer the questionnaires * Patients with pre-capillary PH confirmed by cardiac catheterization (PAPm \> 20mmHg, PCP ≤ 15 mmHg, RVP \> 2UW) having had the right diagnostic cardiac catheterization within one year (≤1 year) : * Cases: Patients with PAH without associated pathology: idiopathic or heritable, or with features of venous/capillary involvement, according to the clinical classification of PH * Controls: Patients with chronic thromboembolic PH (CTEPH, class 4), according to the clinical classification of PH. Exclusion Criteria: * Patients classified as HTP groups 2, 3 or 5 * Patients with a diagnosis of PAH associated with a connective tissue disease, HIV, portal hypertension, congenital heart disease, bilharzia, or a drug or toxic cause considered certain according to the international classification (Aminorex, Benfluorex, Carfilzomib, Dasatinib, Dexfenfluramine, Fenfluramine, Methamphetamines, Mitomycin C, adulterated rapeseed oil) * Patients with signs of right heart failure requiring amines and/or intensive care hospitalization at time of visit (may be included at a later visit) * Patients refusing hair sampling or having no hair \> 2 cm to allow sampling * Patients benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social establishment, adults under legal protection, and patients in emergency situations

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic thromboembolic pulmonary hypertension (cteph) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic thromboembolic pulmonary hypertension pulmonary arterial hypertension pulmonary hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic thromboembolic pulmonary hypertension (cteph) Pulmonary arterial hypertension (PAH)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bordeaux University Hospital

    Bordeaux, France

  • Brest University Hospital

    Brest, France

  • Larrey Hospital

    Toulouse, France

  • Le Kremlin Bicetre Hospital

    Le Kremlin-Bicêtre, France

  • Lille University Hospital

    Lille, France

  • Louis Pradel Hospital

    Lyon, France

  • Nancy University Hospital

    Nancy, France

  • New Civil Hospital

    Strasbourg, France

  • Poitiers University Hospital

    Poitiers, France

  • Saint Etienne University Hospital

    Saint-Etienne, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.